Supporting physical activity engagement in people with Huntington's disease (ENGAGE-HD): study protocol for a randomized controlled feasibility trial by Busse, Monica et al.
TRIALS
Busse et al. Trials 2014, 15:487
http://www.trialsjournal.com/content/15/1/487STUDY PROTOCOL Open AccessSupporting physical activity engagement in
people with Huntington’s disease (ENGAGE-HD):
study protocol for a randomized controlled
feasibility trial
Monica Busse1*, Lori Quinn1, Helen Dawes2, Carys Jones3, Mark Kelson4, Vincent Poile4, Rob Trubey4,
Julia Townson4, Rhiannon Tudor Edwards3, Anne Rosser5 and Kerenza Hood4Abstract
Background: Huntington’s disease (HD) is a complex, single-gene inherited neurodegenerative condition resulting
in symptoms that occur across a wide range of neurological domains, including cognitive, behavioral and motor.
The benefits of regular physical activity for people with HD are widely recognized. However, a number of factors
can prohibit sustained exercise and activity. The purpose of this trial is to explore the feasibility, acceptability and
effectiveness of a physical activity intervention program targeted for people with early- to mid-stage HD.
Methods/Design: The proposed trial is a single blind, multisite, exploratory, randomized controlled feasibility trial of
a physical activity intervention. A total of 62 participants with genetically confirmed HD will be recruited. Each
participant will be involved in the trial for 26 weeks. Participants will be randomized immediately following the
baseline assessment into either a physical activity intervention or a social contact control intervention. The physical
activity intervention is framed around self-determination theory placed within a broader behaviour change wheel
framework. An HD-specific workbook and individual goal setting will be utilized over six 1:1 sessions, with interim
telephone calls. All participants will be reassessed at 16 weeks following the baseline assessment, and then again at
a final follow-up assessment 26 weeks later. At the end of the study, all participants will be offered a brief version of
the alternative intervention, with one home visit and one follow-up telephone call.
Discussion: Engaging and supporting people with HD in a regular physical activity program raises a number of
challenges. The physical activity intervention and the comparator social interaction intervention have been
developed following consultation with people with HD and their families. Each are individually tailored and
determined on individual needs and goals. The results from this trial will provide guidance for the development of
definitive trials.
Trial registration: The trial was registered with ISRCTN (http://www.isrctn.com/ISRCTN65378754) on 13 March 2014.
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Huntington’s disease (HD) is a complex, single-gene inher-
ited condition that produces gradually progressing symp-
toms, usually from mid-life over a 15 to 20-year-period.
Symptoms occur across a wide range of neurological do-
mains, including cognitive, behavioral and motor [1]. The
slowly progressive nature of HD and the current lack of
successful disease-modifying interventions means that rela-
tively young people with the condition are often dependent
on assistance for activities of daily living. Impact on quality
of life and caregiver burden is often great due to the phys-
ical and emotional dependency that develops with greater
disease severity [2-6].
With neurodegenerative diseases, it is now widely recog-
nized that regular and sustained physical activity has the
potential to benefit cardiovascular health [7] and multiple
aspects of physical functioning, including postural control,
gait and health-related quality of life [8-10]. Research has
shown a number of factors which impact on physical ac-
tivity participation, including fluctuations in physical
health, transportation issues, other time conflicts, social
stigma, external demands and lack of motivation [11-13].
In addition, these issues are often further compounded by
disease-specific barriers in the presence of neurodegenera-
tive disease such as HD. Provision of appropriate support
and strategies that are modified to the specific nature of
the disease are crucial, as people with HD may struggle to
participate in regular conventional physical activity or ex-
ercise programs [14]. In the case of HD, challenges are
specific to the triad of motor, cognitive and behavioral
symptoms that are notably complicated by apathy along-
side difficulties in planning and executive function.
Here we present the protocol for a single blind, multi-
site, exploratory, randomized controlled feasibility trial
of a physical activity intervention. The aim of the trial is
to explore the feasibility and acceptability of this inter-
vention for people with early- to mid-stage HD. A range
of outcomes will be explored to assess benefit. As it is
possible that many of the beneficial effects reported in
physical activity interventions are as a direct result of so-
cial activity, the study incorporates a social comparator
arm, involving a structured social intervention, which is
equally matched for contact time.
Methods/Design
Study design
The proposed trial is a single blind, multisite, exploratory,
randomized controlled feasibility trial of a physical activity
intervention. The comparator is a social interaction inter-
vention. The trial schema is illustrated in Figure 1.
Site and participant selection
The trial will be carried out in eight HD specialist clinics,
most of which are Registry/Enroll-HD (NHS ResearchEthics Committee approval numbers: 04/WSE05/89; 13/
WA/0192) sites for the European Huntington’s Disease
Network (EHDN). Many patients attending the HD clinics
are already enrolled in the Registry/Enroll-HD study. The
progression in symptoms of these patients has been
followed by clinicians and researchers for a number of
years. The Registry/Enroll-HD study is a full clinical data-
set, including full medical history and medication history.
One of the optional components within the Registry pro-
ject is the giving of permission by participants to be con-
tacted about other additional and affiliated HD research
projects. In consenting to be enrolled in the Registry/En-
roll-HD study, participants also give their permission for
their coded data to be accessed by researchers conducting
other HD-related research.Inclusion and exclusion criteria
Participants will only be eligible for the trial if they meet
the inclusion and exclusion criteria in Table 1.Recruitment
We aim to recruit 62 participants. At each site, eligible pa-
tients receiving routine HD clinical care or attending for a
Registry/Enroll-HD research assessment will be given in-
formation about the trial and an invitation letter describ-
ing the trial by the clinician responsible for their care. All
interested potential participants will be given a minimum
of 24 hours to read the material and discuss with their
families and carers before any follow-up telephone call, as
per the Registry/Enroll-HD study protocol. They will have
the opportunity to ask any questions they have about the
trial and discuss their potential involvement in the trial.
An invitation letter and information sheet will be sent to
those Registry/Enroll-HD patients who may be eligible,
but not due to visit the clinic imminently (these individ-
uals will be identified from the Registry database with the
assistance of Registry/Enroll-HD investigators at the site).
Telephone follow-up as per the Registry/Enroll-HD study
protocol will then be conducted. The study is eligible for
the National Institute for Health Research Clinical Re-
search Network Portfolio (NIHR CRN). It is possible that
potential participants could see the trial described on this
organization’s website and may express an interest in be-
ing involved. If any person does self-refer to the trial team,
they will be given an information sheet, have the oppor-
tunity to ask any questions they have about the trial and
discuss their potential involvement in the trial. If they are
eligible and not enrolled in the Registry study, potential
participants would be required to be fully reviewed by the
site Principal Investigator (PI) to be assured that the inclu-
sion and exclusion criteria are met. This includes the avail-
ability of genetic confirmation and a recent HD specialist
assessment confirming the status of the disease.
Physical Acvity Group; n = 31
6 visits [week 1, 2, 3, 6, 10, 14]
Assessment 1:  0 weeks; n = 62
Social Interacon Group; n = 31
6 visits [week 1, 2, 3, 6, 10, 14]
End of study  
Screening
Assessment 3: + 26 weeks
Assessment 2: +16 weeks
All parcipants oﬀered brief acvity intervenon
Ethical approval for mul-centre trial
Figure 1 Study schema.
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Informed consent will be obtained from all participants,
including consent to be randomized to either the phys-
ical activity or social interaction groups. Withdrawal of
consent will have no detrimental impact on current and
future treatment. If a participant were to lose their cap-
acity to consent during the trial, the subject will be with-
drawn and no further procedures will be carried out on
the participant. No new personal data will be collected.
Data that has already been collected in relation to the
participant may be retained and used for the purposes
for which consent has already been given, provided they
are effectively anonymized and no longer identifiable to
the research team.
Randomization
Once informed consent is obtained and the first baseline
assessment completed, randomization will be performed
by site staff using the online database. The randomization
ratio to the physical or social intervention will be 1:1. A
minimization technique will be used to achieve, as far as
possible, balance between groups based on data obtainedat the baseline assessment. Variables used for minimization
will be: site of recruitment; age (less than 50-years-old or
50-years-old or greater); gender; Unified Huntington’s Dis-
ease Rating Scale (UHDRS) total motor score (less than 45
or 45 or greater).
Blinding
This is a single blind trial. All data collection will be con-
ducted by a team of blinded assessors specifically trained
in the methodology utilized for the collection of physical
activity and functional assessments. The participants will
be requested by the liaison person to not disclose their al-
location to the assessors. Records of incidents where
blinding is broken will be kept.
Interventions
Physical activity intervention
The ENGAGE-HD physical activity intervention consists
of three main elements, namely the physical activity coach,
a purpose developed exercise DVD (Move to Exercise)
(Cardiff University, Cardiff, United Kingdom) [10,15] and
a purpose-developed physical activity workbook (Figure 2)
Table 1 Participant inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Diagnosis of manifest Huntington’s disease, confirmed by genetic
testing
1. Any physical or psychiatric condition that would prohibit the
participant from completing the intervention or the full battery of
assessments
2. Self-reported or physician-reported difficulties with walking and/or
balance (but still able to walk with minimal assistance) 2. Unable to understand or communicate in spoken English
3. Over 18-years-old 3. Currently involved in any interventional trial or within four weeks of
completing any interventional trial
4. Stable medication regime for four weeks prior to initiation of trial, and
anticipated to be able to maintain a stable regime for the course of trial
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intervention will specifically focus on developing an in-
dividualized lifestyle approach to enhancing physical
activity, where interpersonal interactions of the physical
activity coach are underpinned by the concepts of self-
determination theory (SDT). SDT conceptualizes mo-
tivation for physical activity along a continuum, ranging
from activity that is extrinsically motivated and regu-
lated (in order to gain rewards or to satisfy an external
demand), to activity which is intrinsically motivatedAc
Physical Acvity
Coach
Autonomy supporve interacons
Elicit and acknowledge parcipants perspe
orientaon [link with HD-speciﬁc impairme
Suggest opons with respect to their healt
informaon along with a raonale for any
environment]
Faciliate discussion on opons for improvi
Involve parcipants in decision making
Maximize parcipants’ choices and minim
Tailor advice and support
Relatedness
Act in a warm and caring way, express em
Acknowledge and support paents’ perspe
Avoid judgment and create a sense of shar
Competence
Help to clarify outcome expectaons (wha
that they have made)
Assist in realisc goal-seng and developi
Assist in building skills and idenﬁcaon a
individually developed goals.
Provide posive feedback based on knowl
rather than knowledge of performance (i.e
Provide informaon about physical acvity
regular physical acvity, the challenges rel
acvity, opons for increasing daily physic
Provide examples of how other people wit
exercise programme. Discuss goals and tar
physical acvity goals or targets. This may
to changing physical acvity behavior (e.g.
Provide and support use of a pedometer t
use of exercise diaries to record short term
and inﬂuence planning for physical acvity
Review safety for exercise and monitoring
Inputs
ENGAGE-HD
Physical Acvity
Workbook
Move to Exercise
DVD
Review individual DVD secons based on
Work with the parcipants to idenfy rele
for them
Promote competence/ encourage pracce
exercise DVD
Figure 2 Logic model for the ENGAGE-HD physical activity interventio(autonomous, self-determined behaviour). Conditions
that lead to enhanced and more self-determined motiv-
ation include a supportive social environment that ac-
commodates individual needs, choices and perspectives,
and encourages competence [16,17]. The function of
the additional intervention components, namely a phys-
ical activity workbook and exercise DVD, are to facili-
tate education, enablement, modelling and goal setting.
They are therefore more appropriately placed within a
broader behaviour change wheel (BCW) frameworkvies Outputs
cves and discuss their exercise causality
nts and barriers]
h-related goals and provide relevant
suggesons [consider home support and
ng physical acvity
ize control and pressure
pathy
cves, feelings and values
ed experience
t a person might expect as result of the changes
ng a tailored acvity plan
nd pracce of the acvies required to achieve
edge of results (i.e. acon that is produced)
. movement paerns)
and exercise (for example the beneﬁts of
ated to starng and maintaining regular physical
al acvity)
h HD deal with the challenges of starng a new
gets along with disnct requirements to achieve
include physical or cognive aributes related
self-monitoring, developing speciﬁc rounes
o record regular walking. Provide and support
and longer term physical acvity achievements.
.
of exercise intensity and volume
Behavioral change
Increased and sustained
regular physical acvity
Greater exercise related self-
eﬃcacy
individual’s speciﬁc needs and targets.
vant secons of the DVD that may be appropriate
of skills in using the individual secons of the
Immediate outcomes
Increase in daily physical
acvity
Stability of disease-speciﬁc
measures
Stability of funconal
measures
Improvement in self-eﬃcacy
measures
Improvement in health-related
QoL
Longer term outcomes
Sustained physical acvity
behaviours
Longer term stability of
disease measures and funcon
Longer term health beneﬁts of
regular physical acvity
Behavioral outcomes
Exercise-speciﬁc skill
development
Realisc goal seng and
review
Improved self-monitoring of
physical acvity [pedometers,
exercise diaries, goal review,
progression of exercise]
Competent use of exercise
equipment and DVD
n. HD, Huntington’s Disease; QoL, Quality of Life.
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ability (physical and psychological), opportunity (phys-
ical and social) and motivation (intrinsic and extrinsic)
that produce the observed behaviour.
The logic model developed for this study is provided
in Figure 2. This figure illustrates the key elements (in-
puts), activities and outcomes of the physical activity
intervention for this study.
Participants enrolled in the ENGAGE-HD physical ac-
tivity intervention will receive six home visits and in-
terim telephone calls over a course of 14 weeks, during
which time they will be supported in developing an indi-
vidualized, lifestyle approach to enhancing physical ac-
tivity. These physical activity sessions will be delivered in
each participant’s home by activity coaches, who will
have been trained to deliver the specific intervention
protocol. All activity coaches will either be health profes-
sionals who are able to demonstrate the relevant compe-
tencies for supporting exercise-related activities as set
out within the NHS Knowledge and Skills Framework,
or at least Level 3 Register of Exercise Professionals
(REPS) registered exercise professionals who can provide
clear evidence of meeting these specific competencies.
The intervention delivery will be overseen by the lead
intervention coordinator for the study, who is a regis-
tered physiotherapist. Each coach will undergo one-to-
one training by the lead intervention coordination prior
to the start of the trial at each site. In addition, the
coach and intervention coordinator will dialogue on a
regular basis, including at least one telephone call after a
participant’s first visit, in order to review and discuss
goals and the activity plan. Furthermore, one of the six
sessions for each participant in the physical activity
intervention will be audio recorded and reviewed by the
lead therapist for the monitoring of intervention fidelity.
During the first home visit, the coach will introduce
the participant to the ENGAGE-HD physical activity
intervention, the workbook and the exercise diaries,
which participants will be asked to complete each week.
The initial interactions will consider benefits of physical
activity and each participant’s individual exercise history,
as well as setting specific physical activity goals. Further
discussion topics on physical activity will include imple-
menting a daily activity plan, monitoring exercise inten-
sity, dealing with safety, weather, equipment and typical
barriers (such as time, boredom, lack of equipment, lack
of specific knowledge and support). In the remaining five
home sessions, the coach will continue to support dis-
cussions related to the activities in the workbook, and
supervise the participant performing components of the
Move to Exercise DVD exercise program or other phys-
ical activities. Coaches will also review exercise diaries
completed during the previous week(s). Supportive tele-
phone calls will be conducted three times over the 16-week-period. These calls will serve to provide encour-
agement and advice with respect to the promotion of
regular physical activity. During the calls, the researcher
will also ask about any falls, health or medication
changes and confirm the date and time of the next visit.
Social interaction comparator intervention
Participants assigned to the social interaction group will
receive six visits over the same time period as the phys-
ical activity group. The sessions will also be matched for
time (approximately 45 minutes). The aim of these ses-
sions will be to provide conversational interaction. Each
coach for the social interaction group will undergo one-
to-one training with the lead intervention coordinator
prior to the start of the trial at each site, and the inter-
vention coordinator will be available for consultation
throughout the trial. Each coach will meet with the
participant in their home and will engage with the par-
ticipant in a talking and communication interaction.
Conversation cards (with images and text) representing
a wide range of topics will be used by the researcher to
help direct conversation toward topics of potential inter-
est to the participants during each visit. In the first ses-
sion, a ‘getting to know you’ conversation will take place.
Further discussions may then focus on a range of topics
including travel, media, food, music and art, entertain-
ment, shopping, animals, science, technology, friends
and socializing. At each visit, the coach will complete a
health and falls review with the participant where they
will ask about (and record any details of ) any falls,
health professional interaction or medication changes.
Reminder telephone calls will be conducted three times
over the 16-week-period. These calls will serve to match
the contact time provided to the physical intervention
group. During the calls, the researcher will also ask
about any falls, health or medication changes and con-
firm the date and time of the next visit. At the final
home visit, the participant will be assisted in completing
a life-space assessment and a self-reported physical ac-
tivity assessment. While both of these measures are in-
cluded in the first and third outcome assessments, they
will be gathered by intervention delivery staff at this
time point in order to reduce the risk of un-blinding the
assessment staff.
Screening
A screening log will be kept at each site, where details of
numbers of people who were approached about the trial,
eligibility and whether consent to be contacted was
given or declined will be recorded. A log of any individ-
uals who declined at the initial consent stage will also be
kept. We will ask the recruiting clinicians to keep a rec-
ord of how many individuals have been approached in
relation to the trial.
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Demographic factors of age and gender and level of edu-
cation will be assessed at baseline. Disease burden of
pathology score, physical activity and social support
(using the Social Support for Exercise Survey) [13,19]
will be documented. Participant height and weight, along
with disease-specific measures of motor, cognition and
function [20] will also be documented. Current medica-
tion at baseline and any medication changes at subse-
quent assessments will be recorded.Primary outcomes
The primary feasibility outcome will include an evalu-
ation of eligibility, recruitment and retention rates
(in line with CONSORT recommendations), as well as
monitoring of completion of outcome measures and as-
sessments. The safety of both interventions will be
assessed via records review. Acceptability of the inter-
ventions will be assessed via structured questionnaires
with research participants on completion of the inter-
vention. Process evaluations will further assess whether
the interventions were delivered as intended. This will
be achieved via structured observation of intervention
delivery, semi-structured interviews with intervention
delivery staff and review of intervention records and
participant diaries. These will be presented descriptively
for each of the study groups.Table 2 Outcome measures
Domain to be measured Measure(s)
Measures of participation and health
Individualized quality of life Schedule for the
Self-efficacy Lorig self-efficac
Health service use Client Services R
Health utility measures EQ-5D-5 L [24]
ICECAP-A [25]
Measures of activity
Functional activity Physical perform
Usual pattern of mobility Life space asses
Physical activity assessment International Ph
Walking ability Six-minute walk
Timed Up and G
Self-reported falls Frequency, circu
Measures of body function
Disease-specific clinical measure of motor impairment Unified Hunting
Measure of cognitive impairment Symbol Digit M
Verbal category
Behavioral outcomes
Measures of autonomy/supportive interactions PAS Healthcare
PAS, Perceived Autonomy Support; ICECAP, ICEpop CAPability measure for Adults.Secondary outcomes
A range of secondary measures will be explored in terms
of short-term benefit. Details of which outcomes will be
collected at the different time points are shown in
Table 2 below.
The main assessment of short-term benefit will be
provided by the Physical Performance Test (PPT) [26].
The test incorporates a series of timed tasks that are
summed to give a score between 0 (severe problems)
and 36 (minimal problems). Additional outcome mea-
sures include measures of physical activity and mobility
in the community, self-efficacy, walking ability, health
utility and quality of life. Self-reported physical activity
will be measured using the International Physical Activ-
ity Questionnaire (IPAQ) [28]. Community engagement
will be reflected by the Life Space Assessment [27]. The
Lorig scale will provide a measure of self-efficacy [23].
Walking ability will assessed using the six-minute walk
test [29] and the Timed Up and Go Test [30]. Partici-
pants will be asked to complete the EQ-5D generic
health-related quality of life measure [24] and the “ICE-
pop CAPability measure for Adults” (ICECAP-A) gen-
eric health measure [25] via face-to face interview. An
interview-administered individualized quality of life
measure (SEIQol-DW) [21] will also be obtained at the
final assessment. Self-reported frequency, circumstance
and severity of any falls over the past four months will
be recorded at assessments one and two, and over theevaluation of individual quality of life-direct weighting (SEIQoL-DW) [21]
y scale [22]
eceipt Inventory [23]
ance test (PPT) [26]
sment [27]
ysical Activity Questionnaire (Short Form) [28]
test [29]
o Test [30]
mstance and severity of any falls [31]
ton Disease Rating Scale (UHDRS) modified motor scale [20]
odality Test (SDMT)[32]
fluency [33]
Climate Questionnaire [34]
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care services will be recorded using a Client Services Re-
ceipt Inventory (CSRI) [23] and participants will be
asked to recall contacts (assisted by the main carer
where possible). Where carer assistance is required, this
will be documented. Behavioral outcomes will be
assessed using the Perceived Autonomy Support (PAS)
Healthcare Climate Questionnaire (short form) [34].
Standard clinical measures of disease severity, namely of
motor [1] and cognitive impairment [32,33], will also be
obtained (see Table 2). Health and social care service use
will be costed using national unit costs, so as to assess
the incremental cost-effectiveness of the physical activity
intervention compared to the social contact interven-
tion. The ENGAGE-HD trial schedule of enrolment, in-
terventions and assessments are summarized in Table 3.Sample size
Based on preliminary studies, we can expect a mean
standardized difference between those in the physical ac-
tivity intervention group and those allocated to a control
group (usual care) of 1.8 in the PPT. A more conserva-
tive effect size has been used in sample size calculations
for this study to accommodate for: a) the inclusion of a
social comparator arm in this study rather than no inter-
vention (usual care) and b) the potential of a clustering
effect in the single site pilot study. A total of 46 HD pa-
tients (23 per group) are sufficient to detect a more con-
servative standardized difference of 1.0 at the final
measurement point, with a power of 90% and α of 0.05.
We aim to recruit 62 subjects in total to allow for 25%
loss to follow-up, based on retention rates from our pre-
vious studies. This will allow us to estimate any propor-
tion to within 14.4 percentage points either side, using a
95% confidence interval.Fidelity
Intervention fidelity will be assessed in the following
ways. On completion of each session, the coach will
complete an intervention implementation checklist,
reporting on the component activities of the interven-
tion. At least one of the physical coaching sessions per
participant will be audio or video recorded. The tran-
scripts of these recordings will be used to analyze the
quality of the intervention delivery. Fidelity of the coach
interpersonal interactions will be measured by assessing
the extent to which the coach’s interactions with the par-
ticipant adhered to three elements of SDT, namely au-
tonomy, competence and relatedness. Data from the
PAS Healthcare Climate Questionnaire [34] completed
by participants at assessment two will provide a measure
of the individual coach’s perceived interaction style.
Coach records and diaries will provide an assessment ofuse of the exercise DVD and the purpose-developed
physical activity workbook.
Data management
All assessment and intervention data will be entered by
site staff to a study-specific online database, accessed via
password-protected iPads (Apple Distribution Inter-
national, Hollyhill Industrial Estate Hollyhill, Cork, Re-
public of Ireland) provided to each site. Sites will be
provided with paper versions of the assessment and
intervention forms to be used as a backup, but it is an-
ticipated that most sites will enter data directly into the
database.
Using the online database for data entry will reduce
burden on site staff, and allows for immediate validation
checks upon data entry, which will prompt staff to ad-
dress any questions which have been missed or values
which appear to be outside of an anticipated range. Site
staff will have their own individual login details, which
will ensure that they are only able to access forms and
database functions which are appropriate for their staff
role. Data monitoring will take place on 100% of com-
pleted forms shortly after submission, allowing for timely
query generation and resolution and the minimization of
missing forms or data.
In addition to being used for data entry, study iPads
offer a number of benefits related to training, support
and data monitoring. Following site initiation visits, site
staff will be able to use the iPad to record videos of prac-
tice assessments, for instance, and send these to study
members for feedback. The iPad can also be used by site
staff to communicate with study members via Skype,
allowing for ongoing support in delivering the interven-
tion. Finally, the iPad can be used to audio record se-
lected intervention sessions, which will be used for the
aforementioned assessment of intervention fidelity.
Safety monitoring
An adverse event (AE) is defined as any untoward medical
occurrence in a trial participant. A serious adverse event
(SAE) is any untoward and unexpected medical occur-
rence or effect that results in death; is life-threatening (re-
fers to an event during which the participant was at risk of
death at the time of the event); requires hospitalization, or
prolongation of existing hospitalization; results in persist-
ent or significant disability or incapacity, or is a congenital
abnormality or birth defect. We do not anticipate any
SAEs in this trial cohort, although there is a chance that
some individuals with HD may require hospitalization in
relation to the course of their disease. The most likely rea-
sons for unrelated hospitalization in any person with HD
would be due to respiratory problems and fractures due to
falls. Falls are an expected AE as part of the clinical condi-
tion at this stage of the disease. Related SAEs or AEs are
Table 3 Schedule of enrolment, interventions and assessments
Study period
Enrolment Allocation Post-allocation Follow-up
Time point −4 weeks 0 0 2 weeks 3 weeks 4 weeks 6 weeks 8 weeks 10 weeks 12 weeks 14 weeks 15 weeks 16 weeks 26 weeks
Enrolment
Prescreening from
research database
X
Eligibility screen X
Informed consent X
Registration X
Par-Q safety screening X
Allocation X
Physical intervention:
Physical intervention visits X X X X X X
Audio recording of physical
intervention visit
X
Physical intervention group:
review health and falls record
X X X X X
Physical intervention group:
review exercise diaries
X X X
Telephone calls (physical
intervention)
X X X
Social intervention:
Social intervention visits X X X X X X
Social intervention group:
review health and falls record
X X X X X
Telephone calls (social intervention) X X X
Assessments: X X X
Social support for exercise X
Physical performance test X X X
Self-reported falls X X X
UHDRS functional assessment X X X
UHDRS modified motor
assessment
X X X
Symbol digit modality test X X X
Verbal category fluency X X X
Six-minute walk test X X X
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Table 3 Schedule of enrolment, interventions and assessments (Continued)
Timed up and go test X X X
IPAQ X X X
EQ-5D X X X
ICECAP-A X X X
CSRI X X
Lorig self-efficacy scale X X X
Life space assessment X X X
PAS healthcare climate questionnaire X
SEIQoL-DW X
End of study questionnaire X
UHDRS, Unified Huntington’s Disease Rating Scale; IPAQ, International Physical Activity Questionnaire; CSRI, Client Services Receipt Inventory; SeiQOL-DW, Schedule for the Evaluation of Individual Quality of Life.
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any of the research procedures that are considered causal
to the research process or intervention. While falls can
occur in people with Huntington’s disease, we do not an-
ticipate any increase in fall risk from the ENGAGE-HD
physical activity intervention. Any falls will be recorded
routinely by the research team and submitted for assess-
ment of relatedness as part of the study protocol. The pro-
posed activity intervention is low-to-moderate intensity
and does not involve any heavy load-bearing exercise,
heavy eccentric muscle activity or high intensity activities.
However, some minor muscle soreness or musculoskeletal
strain may occur in the few days following the initiation of
physical activity. This would normally resolve spontan-
eously and would not require any specific interventions or
additional medical care, but will be noted as a potential
expected related AE if reported. All AEs, related adverse
events (RAEs) and SAEs will be recorded using a standard
template and reported in line with standard operating
procedures.
Exploratory statistical and health economics analysis
Summary statistics of demographics (age, gender, height
and weight) and disease burden scores will be reported.
Descriptive data will include an evaluation of eligibility,
recruitment, retention rates and acceptability of, and ad-
herence to the intervention, with 95% confidence inter-
vals. Descriptive analysis of adherence rates according to
baseline measures will be analyzed to inform the assess-
ment of mediators of the intervention. The completion
of outcome measures and assessments will also be re-
ported. Graphical illustration will be used to check dis-
tributions of outcome data.
Successful adherence to the intervention will be de-
fined as having completed visit one, two and three with
their activity coach. Further aspects of adherence will be
measured by the percentage of exercise and falls diaries
completed by participants, and the percentage of partici-
pants who use the physical activity workbooks and exer-
cise DVD. Descriptive analysis of goals set will be
considered in relation to adherence. If retention rates
are greater than the estimated 75%, we will consider this
intervention to be feasible. If the proportion retained is
less than this but greater than 65%, we will consider
adjusting the intervention to increase this in future in-
vestigations. A retention rate lower than this would
require substantial changes to the intervention and
therefore would require further piloting.
Changes at the second assessment in all short-term
secondary outcomes will be analyzed using analysis of
covariance (ANCOVA) with the baseline score of that
variable in addition to the balancing variables (age, gen-
der and UHDRS motor score) as covariates. A logistic
regression analysis will investigate whether the numberof falls experienced differs between the treatment arms.
This will be extended to joint modelling of both falls
and physical functioning if there is a significant differ-
ence in the number of falls experienced. Data may be
transformed to improve model fit, or different regression
approaches used (negative binomial or Poisson regres-
sion). Descriptive analysis of data collected at the third
assessment will be conducted with a view to assessing
any sustained benefit of the intervention (if benefit is
present at assessment two). All these analyses will be on
an intention to treat (ITT) basis, although the primary
analysis will use the complete case data set. In order to
make ITT inferences possible, we will differentiate inter-
vention discontinuation from trial withdrawal and, in
the case of discontinuation, will encourage sites to con-
tinue to collect outcomes data wherever possible. Data
collection will be performed on iPads and data complete-
ness will be monitored at the point of collection, therefore
we do not expect large amounts of missing data. Multiple
imputation of covariates will be performed if the propor-
tion of missingness exceeds 15%. A Complier-Average
Causal Effect (CACE) will also be estimated using multi-
level mixture analysis if non-adherence rates are between
65 and 85% (due to either non-adherence or withdrawal)
[35]. This modelling focuses on estimating the effect of
the interventions in the presence of non-adherence, but
also incorporates adjustments for loss to follow-up associ-
ated with the intervention. A participant will be consid-
ered to be compliant with the intervention if they have
adhered, that is, completed visits one, two and three with
their physical activity coach.
As it is our intention to inform future confirmatory
trials, we will explore the feasibility of outcomes as ap-
plied in this trial and this population. We will consider
internal reliability of all summated scales and assess both
construct and convergent validity of scales not previ-
ously used in HD. In particular, the ordinal scoring cri-
teria for the PPT were developed for application in frail
elderly people. The distribution of the timing measures
will be specifically explored in order to either validate
existing categories or define new categories specific for
application in an HD population. Other measures that
will be investigated for their application in HD include
the IPAQ short form, SEIQol-DW, Life space assess-
ment, ICECAP-A and the Lorig self-efficacy scale. Fi-
nally, we will compare the self-reported falls reported by
patients at assessments (recall), and the falls reported by
patients in their weekly health and falls diaries, in an at-
tempt to validate falls reporting in this population.
A public sector, multi-agency perspective will be used
for the economic evaluation. Exploratory health econom-
ics analyses will be conducted to investigate the patterns
of participants’ health and social care service use, and the
associated costs. Information on health and social care
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http://www.trialsjournal.com/content/15/1/487service use will be collected using a Client Service
Receipt Inventory [23]. The cost of developing the
intervention, training staff and the delivery of the inter-
vention will be calculated. A cost-utility analysis using
the EQ-5D-5 L [24] will be conducted to assess the in-
cremental cost-effectiveness of the physical activity
intervention compared to the social contact intervention,
along with a cost-effectiveness analysis using the ICECAP-
A [25]. We will further present a cost-consequence ana-
lysis of costs and a range of outcome measures for the par-
ticipants. We will conduct two sensitivity analyses related
to staff costs: firstly, we will test the effect of using staff at
a higher and lower grade to conduct the training to deliver
the intervention; secondly, we will test the effect of using
staff at a higher and lower grade to deliver the interven-
tion. We will also conduct a sensitivity analysis removing
the cost of supplying a DVD player to participants.
Process evaluation
At the end of the study, participants will be asked to
complete an end of study questionnaire that focusses on
their views of the trial and of the intervention. We will
also attempt to contact any participants who drop out of
the intervention to ascertain reasons for discontinuing.
Coaching staff will be interviewed to gather their opin-
ions on delivery of the intervention. Topics will include
challenges to intervention delivery, perceived successes,
barriers to implementation and suggestions on how to
improve the intervention process. All the interviews will
be digitally audio recorded and transcribed verbatim for
further analyses. We will employ standard thematic
analysis techniques, which is essentially a process of
summarization, categorization and counting frequency
of responses. The transcripts of interviews will be closely
examined to identify themes and categories. Codes will
be applied to these broad themes, which will then be
broken down further into sub-codes. Agreement on con-
cepts and coding will be sought between members of the
research team to ensure reliability. We will identify com-
monly expressed themes as well as unusual cases. A pro-
portion of the data (20%) will be coded by two different
team members to check on reliability of the coding scheme.
Interviewing will be iterative; where new themes emerge we
will incorporate them into subsequent interviews.
Ethical and regulatory considerations
Multicenter research ethical approval has been granted
by South East Wales Research Ethics Committee B (ap-
proval number: 14/WA/0034). Site-specific approval has
been granted by NHS Grampian (approval number:
NRS14/NE120), Birmingham and Solihull Mental Health
NHS Foundation Trust (approval number: NRR1272),
North Staffordshire Combined NHS Healthcare Trust
(approval number: CHC0101/RD), Sheffield Children’sNHS Foundation Trust (approval number: SCH/14/059),
North Bristol NHS Trust (approval number: 3291), Univer-
sity Hospital Southampton NHS Foundation Trust (ap-
proval number: RHM NEU0229) and Central Manchester
University Hospitals NHS Foundation Trust (approval
number: R03666). Non-NHS site approval has been
granted for Cardiff University (approval number: 14/WA/
1151).
Dissemination policy
Results of this trial will be reported in the first instance to
the funders, and then communicated to participants and
relevant health professionals in a series of open access
publications within nine months of the end of the data
collection. Authorship will follow the trial publication pol-
icy that has been developed based on British Medical Jour-
nal rules on authorship and contributorship.
Discussion
While regular and sustained physical activity has the po-
tential to benefit patients with neurodegenerative condi-
tions such as HD, there are a number of disease-specific
factors, which make it particularly challenging to estab-
lish regular exercise in this population. The intervention
described in the current trial was developed following
wide-ranging consultation with people with HD and
their families, so as to give due consideration and to ac-
commodate the known limiting factors in this popula-
tion. The interpersonal interactions of the intervention
are underpinned by the concepts of SDT placed within a
broader BCW framework. The associated logic model
aids in providing a consistent structure for intervention
delivery and facilitates testing of short and potentially
longer term outcomes in relation to the individual ele-
ments of the intervention. A major emphasis of the inter-
vention is the development of highly individualized
exercise plans. The exercise plans are therefore deter-
mined by individual needs and goals that may change with
disease progression. Such an approach is important in a
neurodegenerative disease so as to promote longer term
disease management in a continually changing arena.
Any physical activity or exercise-based intervention re-
lies heavily on the interaction between the provider
(coach, therapist and/or trainer) and the participant. As
a result, any improvement that may be seen may be, at
least in part, attributed to social interactions. It is there-
fore important for intervention trials to incorporate ac-
tive compactor arms to help reveal the specific effects of
each intervention. Here, rather than having a traditional,
usual care control group, the trial has a comparator arm
which involves half of the participants receiving a series
of social interaction sessions which are time-matched
with the coaching sessions delivered in the intervention
group.
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http://www.trialsjournal.com/content/15/1/487We will consider the acceptability of the interventions
to participants; the ability of centers to recruit partici-
pants; the willingness of participants to be randomized;
the number of eligible participants; the acceptability of
the measures and the time taken to collect data. In this
trial, we have developed an innovative approach to data
collection, monitoring and site support using iPads. In
addition to using iPads as a data entry tool, site staff are
able to use the device to hold regular video conference
calls with research staff, enabling a greater level of day-to-
day support and guidance. The iPads are also being used
to make audio recordings of intervention sessions, in
order to monitor fidelity. We have implemented a variety
of measures to minimize loss to follow-up and missing
data [36]. From a design perspective, we have explicitly
considered the burden with respect to timings of assess-
ments and intervention sessions. The intervention is deliv-
ered in the home, which may be another factor to
minimize loss to follow-up. Adverse events are systematic-
ally documented and, if participants choose to discontinue
the intervention, sites are encouraged to continue with
outcome assessments wherever possible. Finally, data
monitoring is extensive to ensure minimization of missing
forms or data, and analysis will consider imputation
methods as required.
Although measures of effectiveness and cost are being
collected, this trial is not powered for full effectiveness
analysis. The data gathered here will inform the design
(including sample size calculations) and delivery of a con-
firmatory phase three trial. In order to ensure repeatability
in confirmatory trials, reporting will follow the template
for intervention description and replication (TIDieR)
reporting guidelines for description of interventions [37],
and the Consolidated Standards of Reporting Trials
(CONSORT) extension for non-pharmacological interven-
tions [38].Trial status
The trial opened to recruitment in May 2014, with recruit-
ment expected to end in July 2015.Abbreviations
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